1
|
Fan ML, Wei K, Wei XM, Zhang JJ, Hou JG, Shen Q, Sun YS, Li XD, Wang Z, Jiao LL, Li W. Platycodin D restores the intestinal mechanicalbarrier by reducing endoplasmic reticulum stress-mediated apoptosis. J Funct Foods 2022. [DOI: 10.1016/j.jff.2022.105336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
2
|
Stojanova J, Carland JE, Murnion B, Seah V, Siderov J, Lemaitre F. Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic. Front Oncol 2022; 12:959741. [PMID: 36439413 PMCID: PMC9685987 DOI: 10.3389/fonc.2022.959741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 10/07/2022] [Indexed: 11/12/2022] Open
Abstract
Pharmacological therapy is the mainstay of treatment for cancer patients. Despite wide interpatient variability in systemic drug concentrations for numerous antineoplastics, dosing based on body size remains the predominant approach. Therapeutic drug monitoring (TDM) is used for few antineoplastics in specific scenarios. We conducted a rapid bibliometric evaluation of TDM in oncology to capture a snapshot of research in this area over time and explore topics that reflect development in the field. Reports with the composite, indexed term ‘therapeutic drug monitoring’ in the title and abstract were extracted from MEDLINE (inception to August 2021). Reports related to applications in cancer were selected for inclusion and were tagged by study design, antineoplastic drugs and concepts related to TDM. We present a timeline from 1980 to the present indicating the year of first report of antineoplastic agents and key terms. The reports in our sample primarily reflected development and validation of analytical methods with few relating to clinical outcomes to support implementation. Our work emphasises evidence gaps that may contribute to poor uptake of TDM in oncology.
Collapse
Affiliation(s)
- Jana Stojanova
- Department of Clinical Pharmacology and Toxicology, St. Vincent’s Hospital, Sydney, NSW, Australia
- Interdisciplinary Centre for Health Studies (CIESAL), Universidad de Valparaiíso, Valparaiíso, Chile
- *Correspondence: Jana Stojanova,
| | - Jane E. Carland
- Department of Clinical Pharmacology and Toxicology, St. Vincent’s Hospital, Sydney, NSW, Australia
- School of Clinical Medicine, Faculty of Medicine and Health, Sydney, NSW, Australia
| | - Bridin Murnion
- Department of Clinical Pharmacology and Toxicology, St. Vincent’s Hospital, Sydney, NSW, Australia
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - Vincent Seah
- Department of Clinical Pharmacology and Toxicology, St. Vincent’s Hospital, Sydney, NSW, Australia
| | - Jim Siderov
- Pharmacy Department, Austin Health, Heidelberg, VIC, Australia
| | - Florian Lemaitre
- Université de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Rennes, France
- INSERM, Centre d’Investigation Clinique, Rennes, France
| |
Collapse
|